Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EMA’s Multinational Approach Brings All But Two Member States Into New Drug Assessor Fold

Executive Summary

The multinational assessment team (MNAT) approach aimed to involve more EU member states in the evaluation of new medicines. EMA views it as a success, although only about 10% of marketing authorization applications submitted for initial evaluation in 2015 involved MNATs. It will shortly be expanded to certain post-authorization procedures and is being promoted as a tool that will help the agency deal with Brexit fallout.


Related Content

EMA Multinational Assessment Teams Move Into Post-Authorization After Delay
Pharma Execs Urge Post-Brexit Regulatory Deal, As EMA Focuses On Redistribution Of MHRA Work
Brexit: Scenario Planning Well Under Way At EMA
Slowly Does It: The EMA’s Approach To Expanding Multinational Drug Assessment Concept
UK Regulator Has Key Role in One in Four EU-Wide Approvals
Brexit: EMA To Bolster Regulatory Reserves Ahead Of Relocation





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts